drugset / Trial / NCT05089838
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
NaSingle-groupOpen-labelTreatment
Summary
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
Timeline
- Start
- 2021-01-06
- Primary completion
- 2023-10
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMV-TCR-T cells | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | CMV-TCR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |